Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Maravai Lifesciences Holdings (MRVI) Liabilities and Shareholders Equity (2020 - 2025)

Historic Liabilities and Shareholders Equity for Maravai Lifesciences Holdings (MRVI) over the last 6 years, with Q3 2025 value amounting to $849.2 million.

  • Maravai Lifesciences Holdings' Liabilities and Shareholders Equity fell 3356.64% to $849.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $3.7 billion, marking a year-over-year decrease of 3431.04%. This contributed to the annual value of $1.0 billion for FY2024, which is 3221.66% down from last year.
  • Maravai Lifesciences Holdings' Liabilities and Shareholders Equity amounted to $849.2 million in Q3 2025, which was down 3356.64% from $897.0 million recorded in Q2 2025.
  • Maravai Lifesciences Holdings' Liabilities and Shareholders Equity's 5-year high stood at $2.3 billion during Q1 2023, with a 5-year trough of $849.2 million in Q3 2025.
  • Over the past 5 years, Maravai Lifesciences Holdings' median Liabilities and Shareholders Equity value was $1.6 billion (recorded in 2021), while the average stood at $1.7 billion.
  • In the last 5 years, Maravai Lifesciences Holdings' Liabilities and Shareholders Equity soared by 5115.24% in 2022 and then plummeted by 4362.84% in 2024.
  • Maravai Lifesciences Holdings' Liabilities and Shareholders Equity (Quarter) stood at $1.9 billion in 2021, then increased by 18.98% to $2.3 billion in 2022, then plummeted by 34.83% to $1.5 billion in 2023, then tumbled by 32.22% to $1.0 billion in 2024, then decreased by 15.78% to $849.2 million in 2025.
  • Its Liabilities and Shareholders Equity was $849.2 million in Q3 2025, compared to $897.0 million in Q2 2025 and $959.8 million in Q1 2025.